If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02095886","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Randomized","arm_groups":[{"arm_group_label":"Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"},{"arm_group_label":"Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)","arm_group_description":"BMS-955176 single dose by mouth as specified","arm_type":"Experimental"}],"assignment":"Crossover Assignment","brief_summary":"The purpose of this study is to select the best dose level (amount of drug given) and best formulation of the study drug (BMS-955176) to develop further.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Relative bioavailability study with BMS-955176","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:34:48","criteria":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG) measurements and clinical laboratory test results - Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg) / [height (m)]2 - Men and women, ages 18 to 50 years, inclusive - Women must not be of childbearing potential, must not be breastfeeding Exclusion Criteria: - Any significant acute or chronic medical illness - History of cardiac disease or clinically significant cardiac arrhythmias - Current or recent (within 3 months of study drug administration) gastrointestinal disease - Any major surgery within 4 weeks of study drug administration - Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug","detailed_description":"Primary Purpose: Other: This study will assess the bioavailability of BMS-955176 from a micronized crystalline (MC) tablet relative to a spray-dried dispersion (SDD) suspension. Assessment of additional experimental formulations relative to the micronized crystalline tablet will also be performed","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"47","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"babf3e65-dbb7-5bf1-ba22-b2e583a131e9","internal":{"content":null,"contentDigest":"781285d6da574fd360299bf613a10020","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG) measurements and clinical laboratory test results - Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = Weight (kg) / [height (m)]2 - Men and women, ages 18 to 50 years, inclusive - Women must not be of childbearing potential, must not be breastfeeding Exclusion Criteria: - Any significant acute or chronic medical illness - History of cardiac disease or clinically significant cardiac arrhythmias - Current or recent (within 3 months of study drug administration) gastrointestinal disease - Any major surgery within 4 weeks of study drug administration - Any gastrointestinal surgery (including cholecystectomy) that could impact upon the absorption of study drug","interventions":[{"arm_group_label":"Cohort 1 Arm DABC: BMS-955176 (Treatment D, A, B and C)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 2 Arm EFGH: BMS-955176 (Treatment E, F, G and H)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 2 Arm GHEF: BMS-955176 (Treatment G, H, E and F)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 1 Arm CDAB: BMS-955176 (Treatment C, D, A and B)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 2 Arm HEFG: BMS-955176 (Treatment H, E, F and G)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 1 Arm BCDA: BMS-955176 (Treatment B, C, D and A)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 1 Arm ABDC: BMS-955176 (Treatment A, B, D and C)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"},{"arm_group_label":"Cohort 2 Arm FGHE: BMS-955176 (Treatment F, G, H and E)","intervention_description":"BMS-955176","intervention_name":"BMS-955176","intervention_type":"Drug"}],"interventional_subtype":"Other","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":[],"last_follow_up_date":"07/07/2014 00:00:00","links":[],"locations":[{"City":"Nottingham","Latitude":"52.881347","CountryDisplay":"United Kingdom","Longitude":"-1.1472342","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"NG11 6JS","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"50 years","maximum_age":"50","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:45:57","number_of_arms":"8","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"Assessment of BMS-955176 Bioavailability from a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects","org_study_id":"206740","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"07/07/2014 00:00:00","primary_outcomes":[{"outcome_description":"","outcome_measure":"Maximum observed plasma concentration (Cmax) of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Area under the plasma concentration-time curve from time zero to 72 hours post-dose [AUC(0-72)] of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"2013-004896-10","id_type":"EudraCT Number","id_domain":""},{"id":"AI468-034","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"","outcome_measure":"Time of maximum observed plasma concentration (Tmax) of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Terminal plasma half-life (T-HALF) of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Apparent total body clearance (CLT/F) of BMS-955176","outcome_time_frame":"Days 1-4 of Periods 1, 2, 3 and 4","outcome_safety_issue":null},{"outcome_description":"","outcome_measure":"Safety and tolerability based on incidence of adverse events (AEs), serious AEs, AEs leading to discontinuation and deaths, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs and physical examinations","outcome_time_frame":"Up to Period 4/Day 4 (discharge)","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"03/25/2014 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":false}},"pageContext":{"studyId":"206740"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}